ACTION, AWARENESS, HOPE
Don’t miss out on Lung Cancer Awareness Month – Register Today!
November is just around the corner, and now is the time to make your plans to be part of LUNGevity's nationwide movement to raise awareness, honor those impacted by lung cancer, and inspire hope for the future.
You can be a part of Every Breath Forward℠, LUNGevity's national awareness initiative that will fill communities with white flags in honor of those impacted by lung cancer while calling attention to the urgent need for earlier detection, more research, and better treatments.
Order a flag installation kit to create your own meaningful display in your yard or community space.
Breathe Deep
This year's Breathe Deep Together events will take place in Chicago (September 12), Columbus (October 17), and Boston, New York City, and Washington, DC (November 7).
Register today and earn your official event T-shirt by registering and raising $50 by:
- August 14 for Chicago and Columbus
- September 1 for Boston, New York City, and Washington, DC
Can't make it to one of our featured events? Host a Breathe Deep Anywhere event in your own community and make an impact wherever you are.
SCIENCE & RESEARCH CORNER
FDA Approval Expands Options for Treating ROS1+ NSCLC
Treatment options expanded for patients with ROS1+ NSCLC (non-small cell lung cancer). On July 22, 2026, the US FDA approved zidesamtinib for adults with advanced NSCLC whose tumors have ROS1 mutations and who have been previously treated with a ROS1-directed targeted therapy. Learn more about the recent approval here.
2026 WCLC: More Research on the Way
LUNGevity is excited to participate in the 2026 World Conference on Lung Cancer from Sept. 12 – 15 in Seoul, Republic of South Korea. Our research posters and education session will be guiding discussions to optimize care for patients around the world.
We'll also be helping you stay current on the latest lung cancer research presented at the meeting:
- During the conference, follow @LUNGevity on X for live coverage of the #WCLC26 meeting.
- After the conference, be on the lookout for our coverage highlighting the biggest research news.
Don't Miss Out!
Our research newsletter keeps you up to date on all the latest scientific developments in lung cancer. Subscribe now and watch for the next issue coming soon.
Policy and Advocacy in Action
LUNGevity is committed to accelerating science that is driving progress against lung cancer by promoting policies that serve the lung cancer community.
In May, the Office of Management and Budget (OMB) issued a proposed rule that would make significant changes to the way the federal government reviews and awards financial assistance, including research grants through agencies such as the National Institutes of Health (NIH).
The rule contains a number of concerning proposals, including provisions that would give more weight to political appointees in deciding which grants are funded and others that would make it more difficult for researchers to disseminate their work or to collaborate with colleagues in other countries. LUNGevity issued a statement in response to the rule and submitted comments urging OMB to rescind the rule.
In July, LUNGevity joined the American Cancer Society Cancer Action Network and other partners on an amicus brief in support of plaintiffs in the American Academy of Pediatrics v. Kennedy lawsuit. This case is in response to changes the Administration made to the Advisory Committee on Immunization Practices (ACIP) last year. Since that time, recommendations by the new ACIP membership have cast doubt on proven vaccinations that are critical to protecting the health of all Americans, including those who are living with cancer. This case is pending at the U.S. Court of Appeals for the First Circuit. You can read more about the case and the amicus brief in this press release.
To find out how you can be involved in LUNGevity's policy and advocacy work, please visit the LUNGevity Action Network.
Improving Patient Care and Outcomes
Everyone with lung cancer deserves access to the information, care, and treatment options that can help them achieve the best possible outcomes. LUNGevity is working to make that a reality by identifying barriers, bringing together experts and the lung cancer community, and advancing solutions that put people with lung cancer at the center.
From helping ensure biomarker testing results are available when treatment decisions are made to making clinical trials easier to access and participate in, our work is focused on improving the lung cancer experience at every step.
Understanding the Full Picture Before Lung Cancer Treatment Starts
Biomarker testing is a critical part of understanding a person’s specific type of lung cancer that guides the best treatment plans.
However, a notable finding from a national survey published in the American Journal of Clinical Pathology, developed through a collaboration with LUNGevity, the Association for Molecular Pathology, and the American Society for Clinical Pathology, shows that nearly 1/3 of surveyed providers may not have treatment results in time for the appointment with patients when they discuss treatment plans.
This national study takes a close look at how standardized, protocol-driven testing is being used for non-small cell lung cancer and identifies barriers that may delay results.
This research helps us better understand current practices, identify barriers, and continue working toward solutions that support timely access to precision medicine for people with lung cancer. Read the full article.
LUNGevity Leads the Way in Transforming Clinical Trials
Clinical trials are essential to bringing new lung cancer treatments to patients, but they can also place heavy demands on participants and trial sites. A new paper in Clinical Lung Cancer, developed by a LUNGevity Foundation multistakeholder working group, offers practical recommendations to streamline the frequency, conduct, and location of assessments in lung cancer trials. The goal is simple: reduce unnecessary burden while maintaining the scientific rigor needed to evaluate promising therapies.
Through its Transforming Clinical Trials Initiative, LUNGevity continues to lead efforts to make lung cancer clinical research more patient-centric, efficient, and accessible. These recommendations are another step toward clinical trials that better reflect standard-of-care and can be integrated more seamlessly into routine treatment.
Read the full paper and visit the TCTI website to learn more about how LUNGevity is transforming clinical trials for people with lung cancer.
Clinical Trials: What Patients Need to Know
LUNGevity is working to make clinical trials more patient-centric and accessible, and if you are living with lung cancer, understanding how clinical trials work is an important part of making informed treatment decisions. Whether you're newly diagnosed, in treatment, or exploring future options, knowing when and how to ask about clinical trials could expand your treatment choices.
In the latest episode of the Lung Cancer Voices of Hope podcast, small cell lung cancer survivor Wendy Brooks and thoracic oncologist Dr. Arthi Sridhar join hosts Ann Steagall and Dr. Misty Shields to demystify the clinical trial process. Together, they explain how clinical trials are designed to protect participants, address common misconceptions, and discuss why bringing up clinical trials early with your healthcare team can open the door to additional treatment options.
Wendy shares her firsthand experience participating in multiple clinical trials, offering an inspiring perspective on how research not only helped shape her own care, but may help improve treatment for future patients.
Listen to the latest episode and explore LUNGevity's clinical trial resources to learn how clinical trials are advancing lung cancer treatment—and what they could mean for you or someone you love.
Team LUNGevity Heads to the 2027 Double TCS London Marathon
Big news! Team LUNGevity has been selected as a charity partner for the 2027 Double TCS London Marathon, making us a partner for seven of the eight Abbott World Marathon Majors.
This exciting milestone gives runners the opportunity to take on the world's largest marathon while raising critical funds to advance lung cancer research, patient education, and support programs.
Applications for guaranteed race entries are now open and due by August 16, with limited spots available.
Learn how to join Team LUNGevity in London here.
Introducing: The HER2 Virtual Meetup
If you or someone you love is living with HER2-positive lung cancer, you now have a place built just for you. LUNGevity launched a brand-new Virtual Meetup exclusively for the HER2 community, connecting patients, survivors, caregivers, and loved ones who understand this specific journey.
This subtype comes with its own questions, treatment paths, and challenges. Our HER2 Virtual Meetup offers a space to share what's worked, ask what's on your mind, and build real friendships with people who simply get it. Learn more and register here for the August meetup, or here for future HER2 conversations.
LUNGevity hosts monthly Virtual Meetups, including for specific lung cancer types, caregivers, those who have lost a loved one, and general support. This September, we’re also adding new meetups for RET and long-term survivors, along with an added date for those with EGFR. The Thursday Happy Hour, Healing Together, and Caregiver Connection meetups will have new schedules in September, so make sure to check the calendar for all of the new and updated info!
Upcoming: Small Cell SMASHERS Fireside Chat
Friday, August 28 | 12-1 PM ET
Make sure you're following us on YouTube to see the next Small Cell SMASHERS Fireside Chat with Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology and Assistant Professor of Medicine at Harvard Medical School. Dr. Sands will discuss The Importance of HOPE: Highlighting Recent Advancements in SCLC.
If you missed last month's chat, you can watch the recording here
In Case You Missed It
LUNGevity is transforming what it means to be diagnosed and live with lung cancer.
Support our mission by making a tax-deductible donation today.
